Biotech Series B Business Plan Template
Comprehensive business plan template for biotechnology companies ready to raise Series B funding ($20M-$150M). Focus on clinical development, regulatory pathways, and commercial strategy for breakthrough therapeutics.
Frequently Asked Questions
What clinical data do biotech companies need for Series B funding?
Typically Phase II data demonstrating proof-of-concept and clear efficacy signals. Strong safety profile from Phase I studies, biomarker validation, and clear development pathway to approval. The data should support a compelling value proposition for patients and healthcare systems.
How should I present the regulatory strategy for biotech Series B?
Detailed regulatory roadmap with FDA/EMA engagement history, clear approval pathway, risk mitigation for regulatory hurdles, and realistic timelines. Include advisory board input, regulatory counsel involvement, and precedent analysis from similar programs.
What IP considerations are crucial for biotech Series B?
Strong patent estate with composition of matter, method of use, and formulation patents. Freedom-to-operate analysis, competitive IP landscape assessment, and strategy for maintaining exclusivity through commercial launch and beyond.
How do I address the long development timeline in biotech Series B?
Present multiple value inflection points, de-risking milestones, partnership opportunities, and potential exit scenarios. Show how clinical progress creates value independent of ultimate commercial success, including licensing and acquisition possibilities.